You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis

 

Online download statistics by month:

Online download statistics by month: February 2020 to March 2024

AbstractFullPdf
Feb 2020949421
Mar 2020692692226
Apr 2020241241120
May 2020325325161
Jun 202029329353
Jul 202026226265
Aug 202024124164
Sep 202039839890
Oct 2020490491116
Nov 2020421421165
Dec 2020394394104
Jan 2021438438132
Feb 202137037099
Mar 2021722722227
Apr 202137837888
May 202129329376
Jun 202126826870
Jul 202129929949
Aug 202124324387
Sep 202129329364
Oct 202130030083
Nov 202127227380
Dec 202126326353
Jan 202225126389
Feb 202226226479
Mar 202233333967
Apr 202223123551
May 202226927555
Jun 202230831148
Jul 202224424958
Aug 202223323643
Sep 202218218433
Oct 202223123355
Nov 202217818146
Dec 202214014023
Jan 202315115242
Feb 202325725843
Mar 202318818945
Apr 202314114136
May 202317017149
Jun 202316916927
Jul 202314214232
Aug 202315215126
Sep 202317517534
Oct 202314514537
Nov 202312112222
Dec 2023888820
Jan 2024323320
Feb 2024828224
Mar 202412913281
Total12994130523478